A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials
Phytotherapy Research · 2026-08 · 40 (8) · 4737-4758
DOI: 10.1002/ptr.70079 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Phytotherapy Research, online erschienen am 31.08.2025. Verfasst von Mark J Tallon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Legal Products Group Ltd, Ely, Cambridgeshire, UK. Hauptthemen laut MEDLINE: Withania, Teratogens, Abortifacient Agents, Plant Extracts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Withania somnifera (L.) Dunal, commonly known as ashwagandha, has been widely used in Ayurvedic medicine for its adaptogenic properties and therapeutic potential and has been investigated for its benefits related to sleep and stress management by Western medicine. However, concerns regarding its teratogenic and abortifacient effects have emerged following reports from the World Health Organization (WHO) and regulatory bodies. This systematic and ethnobotanical review critically evaluates these claims by assessing ashwagandha's toxicokinetics, toxicodynamics, and available safety data. A comprehensive literature review following PRISMA guidelines was conducted to identify studies on its reproductive toxicity, molecular interactions, and traditional usage. Historical ethnobotanical reports suggest potential abortifacient effects, but citation distortion and lack of primary source validation raise concerns regarding the validity of such claims. Toxicological studies in animal models demonstrate high tolerability, with no significant reproductive toxicity observed at doses relevant to human consumption. Human clinical studies also show no adverse effects on thyroid function, hormonal balance, or reproductive health. Altogether, evidence supporting significant teratogenic or abortifacient activity remains inconclusive. This review highlights the need for standardized, high‐quality research addressing fertility and developmental outcomes in controlled conditions. Given the widespread use of ashwagandha as a dietary supplement ingredient and traditional medicine, a balanced and evidence‐based approach is required to assess its safety, ensuring that regulatory actions are informed by robust scientific data rather than historical speculation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Legal Products Group Ltd, Ely, Cambridgeshire, UK.
- Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Center for Dietary Supplements Research, Fay W. Boozman College of Public Health, Univer…
- Product Safety Labs, Langone Health Grossman School of Medicine, Division of Environmental Medicine, New York City, New York, USA.
ORCID-Profile: Mark J Tallon, Igor Koturbash
Zitieren
APA
Tallon, M. J., Koturbash, I., & Blum, J. L. (2026). A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials. Phytotherapy Research, 40(8), 4737-4758. https://doi.org/10.1002/ptr.70079
Vancouver
Tallon MJ, Koturbash I, Blum JL. A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials. Phytotherapy Research. 2026;40(8):4737-4758. doi:10.1002/ptr.70079
BibTeX
@article{Tallon2026,
author = {Tallon, Mark J and Koturbash, Igor and Blum, Jason L},
title = {A Systematic and Ethnobotanical Review of Ashwagandha's ( Withania Somnifera ) Teratogenic and Abortifacient Potentials},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {8},
pages = {4737--4758},
doi = {10.1002/ptr.70079}
}
EUVIMED